Study protocol: Minimum effective low dose: anti-human thymocyte globulin (MELD-ATG): phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes.

Charlotte Wilhelm BenartziSarah E MillerSylvaine BruggraberDiane PictonMark WilsonKatrina GatleyAnita ChhabraM Loredana MarcovecchioA Emile J HendriksHilde MorobéPiotr Jaroslaw ChmuraSimon BondBärbel Aschemeier-FuchsMikael KnipTimothy TreeLut OverberghJaivier PallOlivier ArnaudMichael J HallerAlmut NitscheAnke M SchulteChantal MathieuAdrian ManderProfessor David Dunger

Published in: BMJ open (2021)

NCT03936634; Pre-results.

Keyphrases

phase ii
clinical trial
low dose
open label
study protocol
endothelial cells
randomized controlled trial
double blind
placebo controlled
phase iii
pluripotent stem cells